Follow
Jodie Palmer
Jodie Palmer
Olivia Newton-John Cancer Research Institute
Verified email at onjcri.org.au
Title
Cited by
Cited by
Year
Frequency of the TMPRSS2: ERG gene fusion is increased in moderate to poorly differentiated prostate cancers
AB Rajput, MA Miller, A De Luca, N Boyd, S Leung, A Hurtado-Coll, ...
Journal of clinical pathology 60 (11), 1238-1243, 2007
2312007
Evaluation of combination nivolumab and ipilimumab immunotherapy in patients with advanced biliary tract cancers: subgroup analysis of a phase 2 nonrandomized clinical trial
O Klein, D Kee, A Nagrial, B Markman, C Underhill, M Michael, L Jackett, ...
JAMA oncology 6 (9), 1405-1409, 2020
1842020
Immunotherapy of ipilimumab and nivolumab in patients with advanced neuroendocrine tumors: a subgroup analysis of the CA209-538 clinical trial for rare cancers
O Klein, D Kee, B Markman, M Michael, C Underhill, MS Carlino, L Jackett, ...
Clinical Cancer Research 26 (17), 4454-4459, 2020
1372020
Androgen-independent growth and tumorigenesis of prostate cancer cells are enhanced by the presence of PKA-differentiated neuroendocrine cells
PD Deeble, ME Cox, HF Frierson Jr, RA Sikes, JB Palmer, RJ Davidson, ...
Cancer research 67 (8), 3663-3672, 2007
742007
A major site of expression of the ets transcription factor Elf5 is epithelia of exocrine glands
EJ Lapinskas, J Palmer, S Ricardo, PJ Hertzog, A Hammacher, ...
Histochemistry and cell biology 122, 521-526, 2004
532004
PTEN loss promotes mitochondrially dependent type II Fas-induced apoptosis via PEA-15
JW Peacock, J Palmer, D Fink, S Ip, EM Pietras, ALF Mui, SW Chung, ...
Molecular and cellular biology, 2009
512009
Comprehensive expression analysis of L-dopa decarboxylase and established neuroendocrine markers in neoadjuvant hormone-treated versus varying Gleason grade prostate tumors
LA Wafa, J Palmer, L Fazli, A Hurtado-Coll, RH Bell, CC Nelson, ...
Human pathology 38 (1), 161-170, 2007
502007
Evaluation of TMB as a predictive biomarker in patients with solid cancers treated with anti-PD-1/CTLA-4 combination immunotherapy
O Klein, D Kee, B Markman, MS Carlino, C Underhill, J Palmer, D Power, ...
Cancer Cell 39 (5), 592-593, 2021
482021
Combination immunotherapy with ipilimumab and nivolumab in patients with advanced adrenocortical carcinoma: a subgroup analysis of CA209-538
O Klein, C Senko, MS Carlino, B Markman, L Jackett, B Gao, C Lum, ...
Oncoimmunology 10 (1), 1908771, 2021
322021
Differential expression and effects of gp130 cytokines and receptors in prostate cancer cells
J Palmer, PJ Hertzog, A Hammacher
The international journal of biochemistry & cell biology 36 (11), 2258-2269, 2004
282004
Constitutive activation of gp130 leads to neuroendocrine differentiation in vitro and in vivo
J Palmer, M Ernst, A Hammacher, PJ Hertzog
The Prostate 62 (3), 282-289, 2005
242005
Demonstration of upregulated H2 relaxin mRNA expression during neuroendocrine differentiation of LNCaP prostate cancer cells and production of biologically active mammalian …
KA Figueiredo, JB Palmer, AL Mui, CC Nelson, ME Cox
Annals of the New York Academy of Sciences 1041 (1), 320-327, 2005
192005
The impact of diet and micronutrient supplements on the expression of neuroendocrine markers in murine Lady transgenic prostate
J Palmer, V Venkateswaran, NE Fleshner, LH Klotz, ME Cox
The Prostate 68 (4), 345-353, 2008
162008
ATIM-23. Preliminary findings of a phase I safety and bioimaging trial of KB004 (ifabotuzumab) in patients with glioblastoma
H Gan, L Cher, P Inglis, Z Lwin, E Lau, U Ackermann, N Coombs, ...
Neuro-Oncology 21 (Supplement_6), vi6-vi6, 2019
132019
A pilot study of intrahepatic yttrium‐90 microsphere radioembolization in combination with intravenous cisplatin for uveal melanoma liver‐only metastases
S Arulananda, S Parakh, J Palmer, M Goodwin, MC Andrews, J Cebon
Cancer Reports 2 (4), e1183, 2019
82019
Combination immunotherapy with nivolumab and ipilimumab in patients with rare gynecological malignancies: results of the CA209-538 clinical trial
O Klein, D Kee, B Gao, B Markman, J da Gama Duarte, L Quigley, ...
Journal for Immunotherapy of Cancer 9 (11), 2021
72021
Combination immunotherapy with ipilimumab and nivolumab in patients with advanced biliary tract cancers.
O Klein, D Kee, A Nagrial, B Markman, C Underhill, M Michael, C Lum, ...
Journal of Clinical Oncology 38 (15_suppl), 4588-4588, 2020
72020
A phase II clinical trial of ipilimumab/nivolumab combination immunotherapy in patients with rare upper gastrointestinal, neuroendocrine, and gynecological malignancies.
O Klein, D Kee, B Markman, R Chang Lee, M Michael, LR Mileshkin, ...
Journal of Clinical Oncology 37 (15_suppl), 2570-2570, 2019
72019
A gut microbial signature for combination immune checkpoint blockade across cancer types
A Gunjur, Y Shao, T Rozday, O Klein, A Mu, BW Haak, B Markman, D Kee, ...
Nature medicine 30 (3), 797-809, 2024
42024
Phase I safety and bioimaging trial of ifabotuzumab in patients with glioblastoma
H Gan, L Cher, PL Inglis, Z Lwin, E Lau, C Wichmann, U Ackermann, ...
Journal of Nuclear Medicine 62 (supplement 1), 104-104, 2021
42021
The system can't perform the operation now. Try again later.
Articles 1–20